Jimmy Ho Cheung Mak

Jimmy Ho Cheung Mak

Auto-generated profile, based on publicly available information

Jimmy Ho Cheung Mak

University of Hong Kong

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2023 in Hepatology
Verified
Journal Article
Closed access
CLChi-Ho Lee
Chi-Ho Lee
LMLung-Yi Loey Mak
Lung-Yi Loey Mak
ETEric Ho Man Tang
Eric Ho Man Tang
DLDavid Tak Wai Lui
David Tak Wai Lui
JMJimmy Ho-Cheung Mak
Jimmy Ho-Cheung Mak
CWCarlos K H Wong
Carlos K H Wong
Background and Aims: Type 2 diabetes (T2D) and chronic hepatitis B infection (CHB) are risk factors of HCC. Sodium glucose co-transporter 2 inhibitors (SGLT2i) inhibit HCC oncogenesis in preclinical studies. However, clinical studies are lacking. This study aimed to evaluate the impact of SGLT2i use on incident HCC using a territory-wide cohort of exclusively patients with co-existing T2D and CHB. Approach and Results: Patients with co-existing T2D and CHB between 2015 and 2020 were identified from the representative electronic database of the Hong Kong Hospital Authority. Patients with and without SGLT2i use were 1:1 matched by propensity score for their demographics, biochemistry results, liver-related characteristics, and background medications. Cox proportional hazards regression model was used to assess the association between SGLT2i use and incident HCC. A total of 2,000 patients with co-existing T2D and CHB (1,000 in each SGLT2i and non-SGLT2i group; 79.7% on anti-HBV therapy at baseline) were included after propensity-score matching. Over a follow-up of 3,704 person-years, the incidence rates of HCC were 1.39 and 2.52 cases per 100 person-year in SGLT2i and non-SGLT2i groups, respectively. SGLT2i use was associated with a significantly lower risk of incident HCC (HR 0.54, 95%CI: 0.33-0.88, p=0.013). The association remained similar regardless of sex, age, glycemic control, diabetes duration, presence of cirrhosis and hepatic steatosis, timing of anti-HBV therapy, and background antidiabetic agents including dipeptidyl peptidase-4 inhibitors, insulin, or glitazones (all p interaction>0.05). Conclusions: Among patients with co-existing T2D and CHB, SGLT2i use was associated with a lower risk of incident HCC.

21 December 2023 in Clinical Endocrinology
Verified
Journal Article
Open access
JMJimmy Ho Cheung Mak
Jimmy Ho Cheung Mak
DLDavid Tak‐Wai Lui
David Tak‐Wai Lui
CFCarol Ho‐Yi Fong
Carol Ho‐Yi Fong
CCChloe Yu‐Yan Cheung
Chloe Yu‐Yan Cheung
YWYing Wong
Ying Wong
CLChi‐Ho Lee
Chi‐Ho Lee
Objective: Baseline circulating thrombospondin‐2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography.Design: Serum TSP2 levels were measured in participants from a randomized, open‐label intervention study, at baseline and after 24‐weeks treatment of either dapagliflozin 10 mg (N = 30) or sitagliptin 100 mg daily (N = 30). Vibration‐controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively.Patients and Measurements: Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p = .012), CAP (p = .015) and LS (p = .011) after 24 weeks.Results: Serum TSP2 level decreased significantly from baseline in dapagliflozin‐treated participants (p = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (r = .487, p = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment.Conclusions: Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.

1 September 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
LLLanlan Li
Lanlan Li
DLDavid Tak Wai Lui
David Tak Wai Lui
CFCarol Ho‐Yi Fong
Carol Ho‐Yi Fong
JMJimmy Ho‐Cheung Mak
Jimmy Ho‐Cheung Mak
CCChloe Yu‐Yan Cheung
Chloe Yu‐Yan Cheung
CLChi‐Ho Lee
Chi‐Ho Lee
Background: In 2023, the American Heart Association established the cardiovascular–kidney–metabolic (CKM) syndrome and defined its different stages. Here, we analyzed the prospective associations of CKM stages with mortality outcomes and how CKM syndrome progresses over time. Methods: This observational study used data from the Hong Kong CRISPS (Cardiovascular Risk Factor Prevalence Study) 2, a population‐based cohort involving community‐dwelling Chinese participants who underwent comprehensive health assessment between 2000 and 2004 and were followed for 20 years. Cox proportional hazards regression models were performed to evaluate the associations between CKM stages and mortality outcomes. Results: A total of 1912 eligible participants were included in the analyses (mean age, 52.5±12.0 years; 46.3% men). At baseline, 240 (12.6%), 240 (12.6%), 1243 (65.0%), 149 (7.8%), 40 (2.1%) had CKM stages 0, 1, 2, 3, and 4, respectively. At 20 years, the adjusted hazard ratios of CKM stages 3 and 4 for all‐cause mortality were 3.8 (95% CI, 1.8–7.9; P <0.001) and 3.7 (95% CI, 1.6–8.3; P =0.002) and for cardiovascular mortality were 17.4 (95% CI, 2.3–133.0; P =0.006) and 21.4 (95% CI, 2.5–187.3; P =0.006), respectively. Among early CKM stages 0 to 2, compared with no CKM at baseline, CKM stage 2 was significantly associated with a higher risk of progression to advanced CKM stages 3 and 4 (odds ratio, 3.9 [95% CI, 2.3–6.7]; P <0.001). Conclusions: Advanced CKM syndrome is associated with long‐term mortality outcomes including all‐cause and cardiovascular death, underscoring the importance of early screening and staging of CKM syndrome to prevent disease progression and reduce mortality risk.